A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors

Exclusion Criteria

• •Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption.
• •Major surgery, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry. Radiation therapy within 2 weeks prior to study entry.
• •Adverse reactions from previous anti-tumor therapy have not yet recovered to ≤ grade 1(excluding hair loss, peripheral neurotoxicity caused by chemotherapy have recovered to ≤ grade 2 ).
• •Autologous hematopoietic stem cell transplantation was performed within 9 months prior to the first dose.
• •History of a second malignancy within 2 years (as defined in the protocol).
• •Active uncontrolled or symptomatic lung disease (as defined in the protocol).
• •Intracranial hypertension or active uncontrolled or symptomatic CNS metastases.
• •Known or suspected hypersensitivity to study medications.
• •Known active uncontrolled or symptomatic CNS metastases.
• •The investigator determined that the patient should not participate in the study.
• •Known mental illness or substance abuse that may disrupt therapy.
• •Clinically significant cardiac abnormalities (as defined in the protocol).
• •Gestating or Lactating women.
• •Pleural effusion, pericardial effusion or ascites that need diuretics or draining within 2 weeks prior to first dose.
• •The patient is currently using a drug known to be a strong inhibitor or inducer of CYP3A4.